Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | FYN | P06241 | 4/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2973415 | 0.88 | DYRK1A (0.51) | DYRK1AFYN | |
| SCHEMBL3542403 | 0.86 | DYRK1A (0.56) | DYRK1AFYN | |
| SCHEMBL2985665 | 0.84 | DYRK1A (0.46) | PIK3CADYRK1APTGS2PTGS1CA12 | |
| SCHEMBL2969001 | 0.84 | CA12 (0.51) | PIK3CAPTGS2CA12CA1CA2 | |
| SCHEMBL2981234 | 0.83 | KIF11 (0.46) | PIK3CADYRK1APTGS2PTGS1CA12 | |
| SCHEMBL2983702 | 0.82 | CA12 (0.48) | PTGS2PTGS1KCNH2CA12CA1 | |
| SCHEMBL2977105 | 0.82 | MEN1 (0.43) | CA12CA1CA2CA9FYN | |
| SCHEMBL2984827 | 0.81 | CA12 (0.43) | PIK3CAPTGS2CA12CA1CA2 | |
| SCHEMBL2985782 | 0.81 | FYN (0.44) | CA12CA1CA2CA9FYN | |
| SCHEMBL2977228 | 0.81 | CA12 (0.48) | PIK3CAPTGS2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-20090042953-A1 | IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES | AEGERA THERAPEUTICS, INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-11-15 | — | — | US | disclosed |
| US-20070238768-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042953-A1 | IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES | PMP22, SMN1; SMN2, BDNF | PIK3CA 2794/4885DYRK1A 3634/4885ALPI 2931/4885 |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | PIK3CA 2635/4885DYRK1A 4068/4885ALPI 2707/4885 |
| US-20070238768-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | PIK3CA 2635/4885DYRK1A 4068/4885ALPI 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.